Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224698 · ClinicalTrials.gov registry record · Phase 2
Inhaled Cannabis for Treatment of PTSD
A Phase 2 study, sponsored by Multidisciplinary Association for Psychedelic Studies.
- Not yet
- Registry status
- Phase 2
- Development phase
- 320
- Enrollment target
NCT07224698 is a Phase 2 study that has not yet begun recruiting, run by Multidisciplinary Association for Psychedelic Studies. The registered enrollment target is 320 participants.
The verdict
NCT07224698, a Phase 2 study, has not yet begun recruiting, sponsored by Multidisciplinary Association for Psychedelic Studies.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 320 participants
- Enrollment target
Study Summary
The rationale for the use of inhalational cannabis to potentially treat PTSD symptoms is based on the many reports of cannabis attenuating PTSD symptom expression among individuals with PTSD, including veterans. Study MJP2 is intended to build off MJP-1 through use of a larger sample size, a parallel study design, and subjective bias mitigation methods to re-examine the use of inhaled high THC-containing cannabis versus placebo for management of PTSD symptoms in a U.S. Veteran sample. Together these studies are intended to provide valuable insights on the already widespread use of cannabis in individuals with PTSD, for which there is currently a lack of controlled evidence available reflective of this real-world use.
Interventions
- DRUG Placebo cannabis
- DRUG High THC Cannabis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2027-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07224698
The ClinicalTrials.gov registry entry for NCT07224698 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Multidisciplinary Association for Psychedelic Studies, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo cannabis is the first listed.
NCT07224698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07224698 about?
NCT07224698 is a clinical study titled "Inhaled Cannabis for Treatment of PTSD". The rationale for the use of inhalational cannabis to potentially treat PTSD symptoms is based on the many reports of cannabis attenuating PTSD symptom expression among individuals with PTSD, including veterans. Study MJP2 is intended to build off MJP-1 through use of a larger sample size, a paralle...
What is the current status of trial NCT07224698?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 320 participants. The study started on 2026-02-01. Estimated completion is 2027-11-30.
What interventions are being tested in trial NCT07224698?
The interventions under investigation include: Placebo cannabis (DRUG), High THC Cannabis (DRUG).
Who is sponsoring clinical trial NCT07224698?
This trial is sponsored by Multidisciplinary Association for Psychedelic Studies, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.